title: Pharmacokinetic study of interleukin-2 following intravenous injection in hemodialysis patients with renal cell carcinoma.
abstract: The purpose of the present study is to determine the change in blood concentration of interleukin-2 (IL-2) after intravenous injection in hemodialysis patients and to assess its safety. Four hemodialysis patients who underwent nephrectomy due to renal cell carcinoma were treated with IL-2 at a dose of 350 000-700 000 JRU by intravenous injection. Pharmacokinetic parameters were analyzed from the serum IL-2 concentration, which reached its peak just after the end of infusion, followed by biphasic elimination, and was below the detection limit in all patients at 24 h postinfusion. In comparison with patients with normal renal function, the volume of distribution in the serum compartment was almost comparable (3820 +/- 2020 mL). Clearance (50.47 +/- 11.50 mL/min) decreased to 40%, and the half-life of the distribution phase (0.45 +/- 0.19 h) and that of the terminal phase (1.72 +/- 0.20 h) were distinctly longer. The area under the blood concentration-time curve was about two-fold higher than that of non-hemodialysis patients. In all patients, there were no serious adverse reactions. The results of the present study suggest that intravenous IL-2 therapy can be safely performed in hemodialysis patients.
authors.affiliation: Department of Urology, Osaka City General Hospital, Miyakojimaku, Osaka, Japan. sakamikawa@msic.med.osaka-cu.ac.jp
authors.forename: Sadanori
authors.initials: S
authors.lastname: Kamikawa
authors.forename: Toshikado
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Asai
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ishii
authors.forename: Taku
authors.initials: T
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D006435:Renal Dialysis; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2